CA2263888A1 - Methods and compositions for the detection of cervical cancer - Google Patents

Methods and compositions for the detection of cervical cancer

Info

Publication number
CA2263888A1
CA2263888A1 CA002263888A CA2263888A CA2263888A1 CA 2263888 A1 CA2263888 A1 CA 2263888A1 CA 002263888 A CA002263888 A CA 002263888A CA 2263888 A CA2263888 A CA 2263888A CA 2263888 A1 CA2263888 A1 CA 2263888A1
Authority
CA
Canada
Prior art keywords
cervical cancer
detection
provides
methods
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002263888A
Other languages
French (fr)
Other versions
CA2263888C (en
Inventor
Susan K. Keesee
Robert Obar
Ying-Jye Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matritech Inc
Original Assignee
Matritech, Inc.
Susan K. Keesee
Robert Obar
Ying-Jye Wu
Milano Acquisition Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matritech, Inc., Susan K. Keesee, Robert Obar, Ying-Jye Wu, Milano Acquisition Corp. filed Critical Matritech, Inc.
Publication of CA2263888A1 publication Critical patent/CA2263888A1/en
Application granted granted Critical
Publication of CA2263888C publication Critical patent/CA2263888C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a wide range of methods and compositions for detecting and treating cervical cancer in an individual.
Specifically, the invention provides target cervical cancer-associated proteins, which permit a rapid detection, preferably before metastases occur, of cervical cancer. The target cervical cancer-associated protein, may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of cervical cancer in an individual. In addition, the invention provides methods utilizing the cervical cancer-associated proteins either as targets for treating cervical cancer or as indicators for monitoring of the efficacy of such a treatment.
CA002263888A 1996-08-30 1997-08-19 Methods and compositions for the detection of cervical cancer Expired - Fee Related CA2263888C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/705,660 US5858683A (en) 1996-08-30 1996-08-30 Methods and compositions for the detection of cervical cancer
US08/705,660 1996-08-30
PCT/US1997/014526 WO1998009170A2 (en) 1996-08-30 1997-08-19 Methods and compositions for the detection of cervical cancer

Publications (2)

Publication Number Publication Date
CA2263888A1 true CA2263888A1 (en) 1998-03-05
CA2263888C CA2263888C (en) 2004-10-26

Family

ID=24834422

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002263888A Expired - Fee Related CA2263888C (en) 1996-08-30 1997-08-19 Methods and compositions for the detection of cervical cancer

Country Status (9)

Country Link
US (4) US5858683A (en)
EP (1) EP0923740B1 (en)
JP (1) JP4116082B2 (en)
AT (1) ATE332505T1 (en)
AU (1) AU4073297A (en)
CA (1) CA2263888C (en)
DE (1) DE69736293T2 (en)
ES (1) ES2268735T3 (en)
WO (1) WO1998009170A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303323B1 (en) 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
JP2000511291A (en) * 1997-10-21 2000-08-29 キャンサー リサーチ キャンペーン テクノロジー リミティド Measurement of abnormal cell proliferation
GB9805477D0 (en) * 1998-03-13 1998-05-13 Oxford Glycosciences Limited Methods and compositions for diagnosis of rheumatoid arthritis
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
DE19829473C2 (en) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Procedure for early diagnosis of carcinomas
DE19855819C2 (en) * 1998-12-03 2001-02-15 Roche Diagnostics Gmbh Stabilization of calibrators containing cytokeratin
US6294349B1 (en) 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6379970B1 (en) * 1999-04-30 2002-04-30 The Arizona Board Of Regents On Behalf Of The University Of Arizona Analysis of differential protein expression
DE60035499T2 (en) 1999-05-17 2008-03-20 Cytyc Corp., Marlborough IDENTIFICATION OF MATERIAL FROM THE MILK CHANNEL OF CHEST
EP1198195A1 (en) * 1999-06-29 2002-04-24 Intercet, Ltd. Human cancer virtual simulation system
US20020009724A1 (en) * 1999-12-08 2002-01-24 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2074201A (en) * 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2002021428A1 (en) * 2000-09-01 2002-03-14 Large Scale Proteomics Corporation Reference database
US6539102B1 (en) 2000-09-01 2003-03-25 Large Scale Proteomics Reference database
US6980674B2 (en) * 2000-09-01 2005-12-27 Large Scale Proteomics Corp. Reference database
EP1202211A3 (en) * 2000-10-26 2004-12-22 Riken Genomic DNA analysis computer program
KR100426454B1 (en) * 2000-11-28 2004-04-13 김진우 Human protooncogene and protein encoded therein
KR100426453B1 (en) * 2000-11-28 2004-04-13 김진우 Human cervical cancer 2 protooncogene and protein encoded by same, expression vector containing same, and cell transformed by said vector
US20030009293A1 (en) * 2001-01-09 2003-01-09 Anderson Norman G. Reference database
AUPR595601A0 (en) 2001-06-27 2001-07-19 International Diabetes Institute Hypoglycaemic peptides and methods of use thereof
KR100472746B1 (en) * 2001-08-13 2005-03-07 김진우 Protooncogene kg-20 and protein encoded therein
US20030138425A1 (en) * 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
EP1333278B1 (en) 2002-02-01 2004-03-10 MTM molecular tools in medicine Methods for monitoring and prognosis of disease course of gastrointestinal tumors
KR100472747B1 (en) * 2002-03-12 2005-03-09 김진우 Human protooncogene and protein encoded therein
EP1369694A1 (en) * 2002-04-09 2003-12-10 MTM Laboratories AG Method for discrimination of metaplasias from neoplastic or preneoplastic lesions
ES2316501T3 (en) * 2002-05-21 2009-04-16 Mtm Laboratories Ag MARKER MOLECULES ASSOCIATED WITH PULMONARY TUMORS.
KR20030094905A (en) * 2002-06-10 2003-12-18 김진우 Mouse oncogene, protein encoded thereby and expression vector containing same
WO2004003203A1 (en) * 2002-06-29 2004-01-08 Jin-Woo Kim Human cervical cancer 5 protooncogene and protein encoded therein
WO2004005514A1 (en) * 2002-07-04 2004-01-15 Jin Woo Kim Human protooncogene 6 and protein encoded therein
DK1388734T3 (en) * 2002-08-01 2004-05-03 Mtm Lab Ag Method for solution-based diagnosis
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
US20040137551A1 (en) * 2003-01-13 2004-07-15 Markovic Nenad S. Cervical acid phosphatase - papanicolaou (CAP-PAP) test kit, method and accesories, processes for producing and using the same
US7291699B2 (en) * 2003-03-18 2007-11-06 The Regents Of The University Of Colorado Product and methods for diagnosis and therapy for cardiac and skeletal muscle disorders
US7361460B2 (en) * 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
ATE289685T1 (en) * 2003-08-25 2005-03-15 Mtm Lab Ag METHOD FOR DETECTING CARCINOMAS IN SOLUBILIZED CERVICAL BODY SAMPLES
JPWO2005043166A1 (en) * 2003-10-30 2007-11-29 シスメックス株式会社 Uterine adenocarcinoma diagnostic agent and adenocarcinoma cell detection method
WO2005054548A2 (en) 2003-11-28 2005-06-16 Invitrogen Corporation Methods, compositions, and kits for protein crystallization
KR20110027823A (en) * 2004-03-24 2011-03-16 트리패스 이미징, 인코포레이티드 Methods and compositions for the detection of cervical disease
US20050221399A1 (en) * 2004-03-30 2005-10-06 Sysmex Corporation Method for screening cervical cancer
US7183057B2 (en) * 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
US7316904B1 (en) 2004-06-30 2008-01-08 Chromodynamics, Inc. Automated pap screening using optical detection of HPV with or without multispectral imaging
ES2732623T3 (en) 2005-01-06 2019-11-25 Innate Pharma Sa Anti-KIR combination treatments and methods
KR100689275B1 (en) 2005-03-30 2007-03-08 김현기 Human protooncogene trg and protein encoded therein
US7595380B2 (en) * 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
US20070015166A1 (en) * 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
US7632498B2 (en) * 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
WO2009015294A1 (en) * 2007-07-24 2009-01-29 Wisconsin Alumni Research Foundation Biomarkers for human papillomavirus-associated cancers
BRPI0913578A2 (en) 2008-05-14 2017-06-06 Dermtech Int diagnosis of melanoma and solar lentigo by nucleic acid analysis
EP2638396B1 (en) 2010-11-12 2017-03-01 incellDX, Inc. Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (cin) lesion from a suspension sample of cervical cells
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
US20160187341A1 (en) * 2013-08-08 2016-06-30 The Research Foundation For The State University Of New York Keratins as biomarkers for cervical cancer and survival
US10449261B2 (en) 2014-07-24 2019-10-22 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
KR20180132807A (en) * 2016-04-07 2018-12-12 케이스 웨스턴 리저브 유니버시티 TDP-43 mitochondrial localization inhibitor for the treatment of neurodegenerative diseases
WO2018148595A1 (en) 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
CA3134936A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
WO1985003132A1 (en) * 1984-01-06 1985-07-18 The Regents Of The University Of California Cytokeratin tumor markers and assays for their detection
JPS6284100A (en) * 1985-10-08 1987-04-17 Dainabotsuto Kk Squamous cell carcinoma-related antigen and immunological utilization thereof
US4882268A (en) * 1985-12-24 1989-11-21 Massachusetts Institute Of Technology Method for determining tissue of origin and degree of malignancy of tumor cells
US5273877A (en) * 1985-12-24 1993-12-28 Massachusetts Institute Of Technology Non-histological cell type determination
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
CA1340245C (en) * 1989-04-21 1998-12-15 John Samuel Monoclonal antibody for differentiation of squamous cell carcinoma antigens and method of use for same
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
ES2147555T3 (en) * 1991-10-31 2000-09-16 Matritech Inc TEST OF NUCLEAR MATRIX PROTEINS IN FLUIDS.
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
US5350835A (en) * 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
DE69333377T2 (en) * 1992-06-22 2004-10-21 Matritech Inc INNOVATIVE MARKER MALIGNER CELL TYPES IN THE INNER NUCLEAR MATRIX
AU5694694A (en) * 1992-12-02 1994-06-22 Denis F. Hochstrasser A method for detecting growing cells using translationally controlled tumor protein p21
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
US5519003A (en) * 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof

Also Published As

Publication number Publication date
WO1998009170A3 (en) 1998-04-23
US20030157482A1 (en) 2003-08-21
US6803189B2 (en) 2004-10-12
WO1998009170A2 (en) 1998-03-05
ES2268735T3 (en) 2007-03-16
DE69736293D1 (en) 2006-08-17
US6027905A (en) 2000-02-22
JP2001500609A (en) 2001-01-16
JP4116082B2 (en) 2008-07-09
ATE332505T1 (en) 2006-07-15
US5858683A (en) 1999-01-12
CA2263888C (en) 2004-10-26
EP0923740B1 (en) 2006-07-05
EP0923740A2 (en) 1999-06-23
AU4073297A (en) 1998-03-19
DE69736293T2 (en) 2007-06-14
US20050164313A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
CA2263888A1 (en) Methods and compositions for the detection of cervical cancer
WO2001036470A3 (en) Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides
CA2285918A1 (en) Methods for concentrating ligands using magnetic particles
AU5794498A (en) Releasable nonvolatile mass-label molecules
CA2331688A1 (en) Detection of a target in a sample
WO1995016919A3 (en) Methods and compositions for the detection of colon cancers
WO2002016412A3 (en) Binding polypeptides for b lymphocyte stimulator protein (blys)
WO2000054046A3 (en) Universal protein array system
WO2005052542A3 (en) Method and composition useful for determining fk 506
WO2002084250A3 (en) Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples
WO1999020756A3 (en) Human toll homologues
WO2003033731A3 (en) Methods for detecting ovarian cancer
AU5062700A (en) Use of a composite polymer-coated sorbent for separation, purification, desalting and concentration of biopolymers
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
EP1113082A3 (en) Amplification capture assay
ES2141249T3 (en) PROCEDURE FOR THE IDENTIFICATION OF HUMAN AND ANIMAL CELLS THAT PRESENT THE CAPACITY FOR UNLIMITED PROLIFERATION OR FOR THE FORMATION OF TUMORS.
CA2317816A1 (en) Peptide detection method
WO1999030165A3 (en) Processes for identifying a solvent condition suitable for determining a biophysical property of a protein
AU5143099A (en) Protein fragment complementation assays for the detection of biological or drug interactions
WO2000043792A3 (en) Methods and kits for sequencing polypeptides
WO2002078636A3 (en) Detection and treatment of colorectal cancer
WO2002075314A3 (en) Detection and treatment of prostate cancer
WO2002077285A3 (en) Methods of determining the presence of polynucleotides employing amplification
WO2000029624A3 (en) Methods and compositions for detection of nucleic acid sequences and signal amplification

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150819